Is Quest Diagnostics Stock a Good Investment?
Quest Diagnostics Investment Advice | DGX |
- Examine Quest Diagnostics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Quest Diagnostics' leadership team and their track record. Good management can help Quest Diagnostics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Quest Diagnostics' business and its evolving consumer preferences.
- Compare Quest Diagnostics' performance and market position to its competitors. Analyze how Quest Diagnostics is positioned in terms of product offerings, innovation, and market share.
- Check if Quest Diagnostics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Quest Diagnostics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Quest Diagnostics Incorporated stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Quest Diagnostics Incorporated is a good investment.
Sell | Buy |
Hold
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Quest Diagnostics Stock
Researching Quest Diagnostics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are held by institutions such as insurance companies. The book value of Quest Diagnostics was currently reported as 60.8. The company has Price/Earnings To Growth (PEG) ratio of 1.83. Quest Diagnostics recorded earning per share (EPS) of 7.43. The entity last dividend was issued on the 14th of January 2025. The firm had 2:1 split on the 21st of June 2005.
To determine if Quest Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Quest Diagnostics' research are outlined below:
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| On 29th of January 2025 Quest Diagnostics paid $ 0.75 per share dividend to its current shareholders | |
| Latest headline from news.google.com: 2,351 Shares in Quest Diagnostics Incorporated Purchased by BankPlus Wealth Management LLC - MarketBeat |
Quest Diagnostics Quarterly Cost Of Revenue |
|
Quest Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Quest Diagnostics Incorporated. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Quest Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Quest Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Quest Diagnostics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2000-04-24 | 2000-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2000-01-27 | 1999-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
1999-01-27 | 1998-12-31 | 0.04 | 0.05 | 0.01 | 25 | ||
1998-07-15 | 1998-06-30 | 0.07 | 0.08 | 0.01 | 14 | ||
1998-01-27 | 1997-12-31 | 0.01 | 0.02 | 0.01 | 100 | ||
1997-07-16 | 1997-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
1999-07-16 | 1999-06-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1997-04-16 | 1997-03-31 | 0.02 | 0.04 | 0.02 | 100 |
Quest Diagnostics Target Price Consensus
Quest target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Quest Diagnostics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Buy |
Most Quest analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Quest stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Quest Diagnostics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationQuest Diagnostics Target Price Projection
Quest Diagnostics' current and average target prices are 164.17 and 170.40, respectively. The current price of Quest Diagnostics is the price at which Quest Diagnostics Incorporated is currently trading. On the other hand, Quest Diagnostics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Quest Diagnostics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Quest Diagnostics Target Price
Quest Diagnostics Analyst Ratings
Quest Diagnostics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Quest Diagnostics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Quest Diagnostics' financials, market performance, and future outlook by experienced professionals. Quest Diagnostics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Quest Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Quest Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Quest Diagnostics Incorporated backward and forwards among themselves. Quest Diagnostics' institutional investor refers to the entity that pools money to purchase Quest Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.7 M | Amvescap Plc. | 2024-09-30 | 1.7 M | Jpmorgan Chase & Co | 2024-09-30 | 1.5 M | Wells Fargo & Co | 2024-09-30 | 1.5 M | Fiduciary Management, Inc. Of Milwaukee | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-09-30 | 1.3 M | Norges Bank | 2024-06-30 | 1.3 M | Fmr Inc | 2024-09-30 | 1.1 M | Northern Trust Corp | 1 M | Vanguard Group Inc | 2024-09-30 | 14 M | Blackrock Inc | 2024-09-30 | 10.1 M |
Quest Diagnostics' market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 17.35 B.Market Cap |
|
Quest Diagnostics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.15 | 0.14 | |
| Return On Capital Employed | 0.09 | 0.10 | |
| Return On Assets | 0.05 | 0.04 | |
| Return On Equity | 0.12 | 0.08 |
Determining Quest Diagnostics' profitability involves analyzing its financial statements and using various financial metrics to determine if Quest Diagnostics is a good buy. For example, gross profit margin measures Quest Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Quest Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Quest Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Quest Diagnostics Incorporated. Check Quest Diagnostics' Beneish M Score to see the likelihood of Quest Diagnostics' management manipulating its earnings.
Evaluate Quest Diagnostics' management efficiency
Quest Diagnostics has Return on Asset of 0.0566 % which means that on every $100 spent on assets, it made $0.0566 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1322 %, implying that it generated $0.1322 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.10 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 7.66 in 2025, whereas Total Assets are likely to drop slightly above 8.5 B in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 51.57 | 54.15 | |
| Tangible Book Value Per Share | (25.47) | (24.20) | |
| Enterprise Value Over EBITDA | 10.52 | 7.35 | |
| Price Book Value Ratio | 2.82 | 3.00 | |
| Enterprise Value Multiple | 10.52 | 7.35 | |
| Price Fair Value | 2.82 | 3.00 | |
| Enterprise Value | 9.7 B | 10.2 B |
At Quest Diagnostics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Basic technical analysis of Quest Stock
As of the 30th of January, Quest Diagnostics holds the Risk Adjusted Performance of 3.0E-4, variance of 1.23, and Coefficient Of Variation of (39,878). Quest Diagnostics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices.Quest Diagnostics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quest Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quest Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Quest Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Prevoznik over two months ago Disposition of 35146 shares by Michael Prevoznik of Quest Diagnostics at 86.63 subject to Rule 16b-3 | ||
Karthik Kuppusamy over three months ago Disposition of 1775 shares by Karthik Kuppusamy of Quest Diagnostics at 156.9156 subject to Rule 16b-3 | ||
Michael Deppe over three months ago Disposition of tradable shares by Michael Deppe of Quest Diagnostics at 125.02 subject to Rule 16b-3 | ||
Sam Samad over six months ago Disposition of 656 shares by Sam Samad of Quest Diagnostics at 126.36 subject to Rule 16b-3 | ||
John Ziegler over a year ago Sale by John Ziegler of 1953 shares of Quest Diagnostics |
Quest Diagnostics' Outstanding Corporate Bonds
Quest Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quest Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quest bonds can be classified according to their maturity, which is the date when Quest Diagnostics Incorporated has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| QUEST DIAGNOSTICS INC Corp BondUS74834LAX82 | View | |
| QUEST DIAGNOSTICS INC Corp BondUS74834LAZ31 | View | |
| US74834LAY65 Corp BondUS74834LAY65 | View | |
| QUEST DIAGNOSTICS INCORPORATED Corp BondUS74834LBB53 | View | |
| US74834LBA70 Corp BondUS74834LBA70 | View | |
| US74834LBC37 Corp BondUS74834LBC37 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Quest Diagnostics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Quest Diagnostics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 3.0E-4 | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 0.8348 | |||
| Coefficient Of Variation | (39,878) | |||
| Standard Deviation | 1.11 | |||
| Variance | 1.23 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 5.02 | |||
| Value At Risk | (1.78) | |||
| Potential Upside | 2.03 | |||
| Skewness | 0.1306 | |||
| Kurtosis | 0.4676 |
| Risk Adjusted Performance | 3.0E-4 | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 0.8348 | |||
| Coefficient Of Variation | (39,878) | |||
| Standard Deviation | 1.11 | |||
| Variance | 1.23 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 5.02 | |||
| Value At Risk | (1.78) | |||
| Potential Upside | 2.03 | |||
| Skewness | 0.1306 | |||
| Kurtosis | 0.4676 |
Consider Quest Diagnostics' intraday indicators
Quest Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Quest Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 203855.0 | |||
| Daily Balance Of Power | 0.6669 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 160.54 | |||
| Day Typical Price | 161.75 | |||
| Price Action Indicator | 8.0 | |||
| Period Momentum Indicator | 8.73 |
Quest Diagnostics Corporate Filings
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 23rd of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 22nd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 16th of August 2024 Prospectus used primarily for registering securities for public sale. | ViewVerify |
Quest Stock media impact
Far too much social signal, news, headlines, and media speculation about Quest Diagnostics that are available to investors today. That information is available publicly through Quest media outlets and privately through word of mouth or via Quest internal channels. However, regardless of the origin, that massive amount of Quest data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Quest Diagnostics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Quest Diagnostics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Quest Diagnostics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Quest Diagnostics alpha.
Quest Diagnostics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Quest Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Quest Diagnostics Historical Investor Sentiment
Investor biases related to Quest Diagnostics' public news can be used to forecast risks associated with an investment in Quest. The trend in average sentiment can be used to explain how an investor holding Quest can time the market purely based on public headlines and social activities around Quest Diagnostics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Quest Diagnostics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Quest Diagnostics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Quest Diagnostics news discussions. The higher the estimate score, the more favorable the investor's outlook on Quest Diagnostics.
Quest Diagnostics Maximum Pain Price Across March 21st 2025 Option Contracts
Quest Diagnostics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Quest Diagnostics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Quest Diagnostics' options.
Quest Diagnostics Corporate Directors
| Gail Wilensky | Independent Director | Profile | |
| Wright Lassiter | Independent Director | Profile | |
| Gary Pfeiffer | Independent Director | Profile | |
| Vicky Gregg | Independent Director | Profile |
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.